Prof. Dr. Moseley Harry
University of Dundee, Ninewells Hospital & Medical School, Dundee, United Kingdom
Update on photodynamic therapy for skin lesions
Author: Harry Moseley
Photodynamic Therapy (PDT) is widely used in the treatment of non-melanoma skin cancers and pre-cancerous skin lesions. This presentation will bring an update principally with regard to treatment guidelines approved by the British Association of Dermatologists (BAD) and daylight PDT. The BAD reviewed all relevant literature and from this made strong recommendations that topical PDT should be provided as a treatment option for patients with superficial basal cell carcinoma (BCC), thin nodular BCC, squamous cell carcinoma (SCC) in situ (Bowen’s disease), and actinic keratosis (AK). AK requires treatment that is field-directed and is well-suited to PDT. Conventional PDT involves application of a pro-drug and, 3 hours later red light illumination using an LED in a hospital setting. The use of daylight as an alternative light source has been studied in several locations worldwide. Weather conditions could limit its usefulness, and so we have recently undertaken daylight PDT in Scotland to see if it is feasible in such a northern location. We have been able to demonstrate that daylight PDT in Scotland is an effective treatment strategy with 73% of patients achieving clearance or a good therapeutic response.
Harry Moseley, PhD FinstP MBA, has an active interest in biophysical aspects of lasers and ultra-violet radiation. Prior to entering semi-retirement, Professor Moseley directed a very active research programme in the Photobiology Unit, set up an accredited calibration laboratory, in addition to a significant clinical workload, particularly with regard to laser treatments. Prof Moseley is Emeritus President of the British Medical Laser Association, is a Board member of the European Laser Association and Fellow of the American Society of Lasers in Surgery and Medicine. He also serves on several national and international committees and was previously an advisor to the European Union on health effects of new forms of artificial lighting. He has served on several committees of the British Association of Dermatologists and is a founding director of the Scottish PDT Centre.